The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study

被引：0
|
作者：
Stuart J. McGurnaghan
Liam Brierley
Thomas M. Caparrotta
Paul M. McKeigue
Luke A. K. Blackbourn
Sarah H. Wild
Graham P. Leese
Rory J. McCrimmon
John A. McKnight
Ewan R. Pearson
John R. Petrie
Naveed Sattar
Helen M. Colhoun
机构：
[1] University of Edinburgh,MRC Institute of Genetics and Molecular Medicine
[2] Western General Hospital,Usher Institute of Population Health Sciences and Informatics
[3] University of Edinburgh,Institute of Cardiovascular and Medical Sciences
[4] Ninewells Hospital and Medical School,undefined
[5] University of Glasgow,undefined
来源：
Diabetologia | 2019年 / 62卷
关键词：
Dapagliflozin; Glycaemic control; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：621 / 632
页数：11
相关论文
共 50 条
  • [1] The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study
    McGurnaghan, Stuart J.
    Brierley, Liam
    Caparrotta, Thomas M.
    McKeigue, Paul M.
    Blackbourn, Luke A. K.
    Wild, Sarah H.
    Leese, Graham P.
    McCrimmon, Rory J.
    McKnight, John A.
    Pearson, Ewan R.
    Petrie, John R.
    Sattar, Naveed
    Colhoun, Helen M.
    [J]. DIABETOLOGIA, 2019, 62 (04) : 621 - 632
  • [2] The effectiveness of dapagliflozin and lixisenatide in managing Type 2 diabetes: a real-world observational study
    Duffy, A.
    Smith, C.
    Harrow, C.
    McGowan, N.
    McIntyre, M.
    So, B.
    Jones, C.
    Gonzalez, N.
    [J]. DIABETIC MEDICINE, 2016, 33 : 166 - 166
  • [3] Glycaemic control and other cardiovascular risk factors should be targeted independently in patients with type 2 diabetes mellitus
    Stephens, J. W.
    Carman, J. E.
    Prior, S. L.
    Jones, D. A.
    Price, D. E.
    [J]. ATHEROSCLEROSIS, 2011, 217 (01) : 297 - 298
  • [4] An audit of glycaemic control and cardiovascular risk factors in patients with type 2 diabetes mellitus
    P. Downey
    L. O’Shea
    D. Dillon
    M. Corbett
    S. Sreenan
    [J]. Irish Journal of Medical Science, 2002, 171 (Suppl 5) : 11 - 12
  • [5] Efficacy of linagliptin on cardiovascular risk and cardiometabolic parameters in Thai patients with type 2 diabetes mellitus: A real-world observational study
    Poonchuay, Natnicha
    Wattana, Konkanok
    Uitrakul, Suriyon
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2022, 16 (05)
  • [6] C-peptide, glycaemic control, and diabetic complications in type 2 diabetes mellitus: A real-world study
    Huang, Yajing
    Wang, Yahao
    Liu, Chuanfeng
    Zhou, Yue
    Wang, Xiang
    Cheng, Bingfei
    Kui, Che
    Wang, Yangang
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2022, 38 (04)
  • [7] VIEW-Iran: A real-world study of liraglutide effectiveness on glycaemic control in people with type 2 diabetes mellitus
    Khamseh, M. E.
    Hosseinpanah, F.
    Malek, M.
    Damavandi, M. H.
    Thamattoor, U. K.
    Kaltoft, M. S.
    Esteghamati, A.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [8] An audit of glycaemic control and cardiovascular risk factors in patients with type 1 diabetes mellitus
    P. Downey
    L. O’Shea
    D. Dillon
    M. Corbett
    S. Sreenan
    [J]. Irish Journal of Medical Science, 2002, 171 (Suppl 5) : 11 - 11
  • [9] Efficacy of vildagliptin on 10-year cardiovascular risk reduction in Thai patients with type 2 diabetes mellitus: A real-world observational study
    Wattana, Konkanok
    Poonchuay, Natnicha
    Uitrakul, Suriyon
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2022, 16 (03)
  • [10] Real world evidence for legacy effect of early glycaemic control in type 2 diabetes on risk of macrovascular disease
    Whyte, M.
    Hoang, U.
    Hinton, W.
    McGovern, A. P.
    Munro, N.
    de Lusignan, S.
    [J]. DIABETOLOGIA, 2017, 60 : S523 - S524
12345